- Home
- SRPT vs DNLI Comparison
SRPT vs DNLI Comparison
Compare SRPT & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRPT | DNLI |
|---|---|---|
| Founded | 1980 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.5B |
| IPO Year | 1997 | 2017 |
Fundamental Metrics
Financial Performance| Metric | SRPT | DNLI |
|---|---|---|
| Price | $21.00 | $19.05 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 28 | 13 |
| Target Price | $26.00 | ★ $32.64 |
| AVG Volume (30 Days) | ★ 6.1M | 1.4M |
| Earning Date | 11-03-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,413,715,000.00 | N/A |
| Revenue This Year | $10.20 | N/A |
| Revenue Next Year | N/A | $94,232.03 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 47.15 | N/A |
| 52 Week Low | $10.42 | $10.57 |
| 52 Week High | $138.81 | $26.18 |
Technical Indicators
Market Signals| Indicator | SRPT | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 56.81 | 67.04 |
| Support Level | $15.94 | $18.74 |
| Resistance Level | $21.21 | $19.63 |
| Average True Range (ATR) | 1.26 | 1.11 |
| MACD | 0.42 | 0.23 |
| Stochastic Oscillator | 96.02 | 87.19 |
Price Performance
Historical ComparisonAbout SRPT Sarepta Therapeutics Inc. (DE)
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.